Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses

OncoImmunology

Volumn 5, Issue 10, 2016, Pages

  Colluru, Viswa Teja ^a,b   Zahm, Christopher D ^b   McNeel, Douglas G ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Antigen expression; DNA vaccine; LAG3; mini intronic plasmid; tolerance

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; HLA DR1 ANTIGEN; HLA DR11 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; TUMOR ANTIGEN; TUMOR SPECIFIC ANTIGEN SSX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MALE; MINI INTRONIC PLASMID; MOUSE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT;

EID: 84988723111     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1223002     Document Type: Article

References (59)

1. J.A.Wolff, R.W.Malone, P.Williams, W.Chong, G.Acsadi, A.Jani, P.L.Felgner. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; PMID:1690918; http://dx.doi.org/10.1126/science.1690918
2. G.Zhang, V.Budker, J.A.Wolff. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10:1735-7; PMID:10428218; http://dx.doi.org/10.1089/10430349950017734
3. M.A.Liu. DNA vaccines:an historical perspective and view to the future. Immunol Rev 2011; 239:62-84; PMID:21198665; http://dx.doi.org/10.1111/j.1600-065X.2010.00980.x
4. J.B.Ulmer, J.J.Donnelly, S.E.Parker, G.H.Rhodes, P.L.Felgner, V.J.Dwarki, S.H.Gromkowski, R.R.Deck, C.M.DeWitt, A.Friedman. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9; PMID:8456302; http://dx.doi.org/10.1126/science.8456302
5. V.T.Colluru, L.E.Johnson, B.M.Olson, D.G.McNeel. Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol Semin Orig Investig 2016; 34:193-204; PMID:24332642; http://dx.doi.org/10.1016/j.urolonc.2013.09.014
6. V.Fowler, L.Robinson, B.Bankowski, S.Cox, S.Parida, C.Lawlor, D.Gibson, F.O'Brien, B.Ellefsen, D.Hannaman et al. A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease. Antiviral Res 2012; 94:25-34; PMID:22330893; http://dx.doi.org/10.1016/j.antiviral.2012.02.002
7. G.Vandermeulen, H.Richiardi, V.Escriou, J.Ni, P.Fournier, V.Schirrmacher, D.Scherman, V.Préat. Skin-specific promoters for genetic immunisation by DNA electroporation. Vaccine 2009; 27:4272-7; PMID:19450641; http://dx.doi.org/10.1016/j.vaccine.2009.05.022
8. H.Hon, A.Oran, T.Brocker, J.Jacob. B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol 2005; 174:5233-42; PMID:15843519; http://dx.doi.org/10.4049/jimmunol.174.9.5233
9. K.Ito, K.Ito, N.Shinohara, S.Kato. DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response. Mol Immunol 2003; 39:847-54; PMID:12686500; http://dx.doi.org/10.1016/S0161-5890(03)00024-5
10. H.Lauterbach, A.Gruber, C.Ried, C.Cheminay, T.Brocker. Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination. J Immunol 2006; 176:4600-7; PMID:16585550; http://dx.doi.org/10.4049/jimmunol.176.8.4600
11. A.Porgador, K.R.Irvine, A.Iwasaki, B.H.Barber, N.P.Restifo, R.N.Germain. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188:1075-82; PMID:9743526; http://dx.doi.org/10.1084/jem.188.6.1075
12. T.Nguyen-Hoai, D.Kobelt, O.Hohn, M.D.Vu, P.M.Schlag, B.Dörken, S.Norley, M.Lipp, W.Walther, A.Pezzutto et al. HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model:Gene gun is superior to jet injector in inducing CTL responses and protective immunity. Oncoimmunology 2012; 1:1537-45; PMID:23264900; http://dx.doi.org/10.4161/onci.22563
13. D.H.Amante, T.R.F.Smith, J.M.Mendoza, K.Schultheis, J.R.McCoy, A.S.Khan, N.Y.Sardesai, K.E.Broderick. Skin transfection patterns and expression kinetics of electroporation-enhanced plasmid delivery using the CELLECTRA-3P, a Portable next-generation dermal electroporation device. Hum Gene Ther Methods 2015; 26:134-46; PMID:26222896; http://dx.doi.org/10.1089/hgtb.2015.020
14. T.Choi, M.Huang, C.Gorman, R.Jaenisch. A generic intron increases gene expression in transgenic mice. Mol Cell Biol 1991; 11:3070-4; PMID:2038318; http://dx.doi.org/10.1128/MCB.11.6.3070
15. S.André, B.Seed, J.Eberle, W.Schraut, A.Bültmann, J.Haas. Increased Immune Response Elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usages. J Virol 1998; 72:1497-503
16. T.Nagata, M.Uchijima, A.Yoshida, M.Kawashima, Y.Koide. Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells:analysis of plasmid DNA encoding a CTL epitope derived from microorganisms. Biochem Biophys Res Commun 1999; 261:445-51; PMID:10425204; http://dx.doi.org/10.1006/bbrc.1999.1050
17. W.Jechlinger. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 2006; 5:803-25; PMID:17184219; http://dx.doi.org/10.1586/14760584.5.6.803
18. Z.-L.Xu, H.Mizuguchi, A.Ishii-Watabe, E.Uchida, T.Mayumi, T.Hayakawa. Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 2001; 272:149-56; PMID:11470520; http://dx.doi.org/10.1016/S0378-1119(01)00550-9
19. Z.-Y.Chen, C.-Y.He, A.Ehrhardt, M.A.Kay. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther J Am Soc Gene Ther 2003; 8:495-500; PMID:12946323; http://dx.doi.org/10.1016/S1525-0016(03)00168-0
20. J.Lu, F.Zhang, M.A.Kay. A Mini-intronic Plasmid (MIP):A novel robust transgene expression vector in vivo and in vitro. Mol Ther [Internet] 2013 [cited 2013Mar6]; Available from:http://www.nature.com/mt/journal/vaop/ncurrent/full/mt201333a.html
21. J.Lu, F.Zhang, S.Xu, A.Z.Fire, M.A.Kay. The extragenic spacer length between the 5|[prime]| and 3|[prime]| Ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors. Mol Ther [Internet] 2012 [cited 2012Sep21]; Available from:http://www.nature.com/mt/journal/vaop/ncurrent/full/mt201265a.html
22. A.-K.Roos, F.Eriksson, J.A.Timmons, J.Gerhardt, U.Nyman, L.Gudmundsdotter, A.Bråve, B.Wahren, P.Pisa. Skin electroporation:Effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE [Internet] 2009 [cited 2016Mar14]; 4. Available from:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748717/
23. I.H.Lee, J.-B.Park, M.Cheong, Y.S.Choi, D.Park, J.-I.Sin. Antitumor therapeutic and antimetastatic activity of electroporation-delivered human papillomavirus 16 E7 DNA vaccines:a possible mechanism for enhanced tumor control. DNA Cell Biol 2011; 30:975-85; PMID:21649506; http://dx.doi.org/10.1089/dna.2011.1266
24. K.J.Stacey, I.L.Ross, D.A.Hume. Electroporation and DNA-dependent cell death in murine macrophages. Immunol Cell Biol 1993; 71 (Pt 2):75-85; PMID:8486399; http://dx.doi.org/10.1038/icb.1993.8
25. Q.Wang, W.Jiang, Y.Chen, P.Liu, C.Sheng, S.Chen, H.Zhang, C.Pan, S.Gao, W.Huang. In Vivo Electroporation of Minicircle DNA as a Novel Method of Vaccine Delivery To Enhance HIV-1-Specific Immune Responses. J Virol 2014; 88:1924-34; PMID:24284319; http://dx.doi.org/10.1128/JVI.02757-13
26. W.M.Dietz, N.E.B.Skinner, S.E.Hamilton, M.D.Jund, S.M.Heitfeld, A.J.Litterman, P.Hwu, Z.-Y.Chen, A.M.Salazar, J.R.Ohlfest et al. Minicircle DNA is Superior to Plasmid DNA in Eliciting Antigen-specific CD8+ T-cell Responses. Mol Ther [Internet] 2013 [cited 2013May22]; Available from:http://www.nature.com/mt/journal/vaop/ncurrent/full/mt201385a.html
27. H.A.Smith, D.G.McNeel. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother Hagerstown Md 1997 2011; 34:569-80; PMID:21904219; http://dx.doi.org/10.1097/CJI.0b013e31822b5b1d
28. H.A.Smith, B.T.Rekoske, D.G.McNeel. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine 2014; 32:1707-15; PMID:24492013; http://dx.doi.org/10.1016/j.vaccine.2014.01.048
29. B.T.Rekoske, H.A.Smith, B.M.Olson, B.B.Maricque, D.G.McNeel. PD-1 or PD-L1 blockade restores antitumor efficacy following SSX2 Epitope-modified DNA vaccine immunization. Cancer Immunol Res 2015; 3:946-55; PMID:26041735; http://dx.doi.org/10.1158/2326-6066.CIR-14-0206
30. H.A.Smith, R.J.Cronk, J.M.Lang, D.G.McNeel. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res 2011; 71:6785-95; PMID:21880588; http://dx.doi.org/10.1158/0008-5472.CAN-11-2127
31. H.A.Smith, D.G.McNeel. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother Hagerstown Md 1997 2011; 34:569-80; PMID:21904219; http://dx.doi.org/10.1097/CJI.0b013e31822b5b1d
32. J.Luke, A.E.Carnes, C.P.Hodgson, J.A.Williams. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 2009; 27:6454-9; PMID:19559109; http://dx.doi.org/10.1016/j.vaccine.2009.06.017
33. L.E.G.Maniar, J.M.Maniar, Z.-Y.Chen, J.Lu, A.Z.Fire, M.A.Kay. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol Ther [Internet] 2012 [cited 2012Nov29]; Available from:http://www.nature.com/mt/journal/vaop/ncurrent/full/mt2012244a.html
34. D.Kobelt, M.Schleef, M.Schmeer, J.Aumann, P.M.Schlag, W.Walther. Performance of high quality minicircle DNA for in vitro and in vivo gene transfer. Mol Biotechnol 2013; 53:80-9; PMID:22467123; http://dx.doi.org/10.1007/s12033-012-9535-6
35. Darquet AM, Rangara R, Kreiss P, Schwartz B, Naimi S, Delaére P, Crouzet J, Scherman D. Minicircle:an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther 1999; 6:209-18; PMID:10435105; http://dx.doi.org/10.1038/sj.gt.3300816
36. C.P.A.Alves, M.Šimčíková, L.Brito, G.A.Monteiro, D.M.F.Prazeres. Development of a nicking endonuclease-assisted method for the purification of minicircles. J Chromatogr A [Internet] [cited 2016Mar28]; Available from:http://www.sciencedirect.com/science/article/pii/S0021967316303004; PMID:AMBIGUOUS
37. J.F.Grosso, M.V.Goldberg, D.Getnet, T.C.Bruno, H.-R.Yen, K.J.Pyle, E.Hipkiss, D.A.A.Vignali, D.M.Pardoll, C.G.Drake. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009; 182:6659-69; PMID:19454660; http://dx.doi.org/10.4049/jimmunol.0804211
38. C.M.Bucks, J.A.Norton, A.C.Boesteanu, Y.M.Mueller, P.D.Katsikis. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol Baltim Md 1950 2009; 182:6697-708; PMID:1945466; http://dx.doi.org/10.4049/jimmunol.0800997
39. S.D.Blackburn, H.Shin, W.N.Haining, T.Zou, C.J.Workman, A.Polley, M.R.Betts, G.J.Freeman, D.A.A.Vignali, E.J.Wherry. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10:29-37; PMID:19043418; http://dx.doi.org/10.1038/ni.1679
40. M.V.Goldberg, C.G.Drake. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol 2011; 344:269-78; PMID:21086108; http://dx.doi.org/10.1007/82_2010_114
41. S.Weijzen, S.C.Meredith, M.P.Velders, A.G.Elmishad, H.Schreiber, W.M.Kast. Pharmacokinetic differences between a T Cell-Tolerizing and a T cell-activating peptide. J Immunol 2001; 166:7151-7; PMID:11390461; http://dx.doi.org/10.4049/jimmunol.166.12.7151
42. A.E.Denton, R.Wesselingh, S.Gras, C.Guillonneau, M.R.Olson, J.D.Mintern, W.Zeng, D.C.Jackson, J.Rossjohn, P.D.Hodgkin et al. Affinity thresholds for naive CD8+ CTL activation by peptides and engineered influenza a viruses. J Immunol 2011; 187:5733-44; PMID:22039305; http://dx.doi.org/10.4049/jimmunol.1003937
43. M.S.Kim, J.-I.Sin. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology 2005; 116:255-66; PMID:16162274; http://dx.doi.org/10.1111/j.1365-2567.2005.02219.x
44. P.K.Chattopadhyay, J.Yu, M.Roederer. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 2005; 11:1113-7; PMID:16186817; http://dx.doi.org/10.1038/nm1293
45. R.G.van der Most, K.Murali-Krishna, J.G.Lanier, E.J.Wherry, M.T.Puglielli, J.N.Blattman, A.Sette, R.Ahmed. Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology 2003; 315:93-102; PMID:14592762; http://dx.doi.org/10.1016/j.virol.2003.07.001
46. E.J.Wherry, J.N.Blattman, K.Murali-Krishna, R.van der Most, R.Ahmed. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77:4911-27; PMID:12663797; http://dx.doi.org/10.1128/JVI.77.8.4911-4927.2003
47. T.Kouo, L.Huang, A.B.Pucsek, M.Cao, S.Solt, T.Armstrong, E.Jaffee. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T Cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res 2015; 3:412-23; PMID:25691328; http://dx.doi.org/10.1158/2326-6066.CIR-14-0150
48. J.F.Grosso, C.C.Kelleher, T.J.Harris, C.H.Maris, E.L.Hipkiss, A.De Marzo, R.Anders, G.Netto, D.Getnet, T.C.Bruno et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007; 117:3383-92; PMID:17932562; http://dx.doi.org/10.1172/JCI31184
49. S.Sierro, P.Romero, D.E.Speiser. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011; 15:91-101; PMID:21142803; http://dx.doi.org/10.1517/14712598.2011.540563
50. N.Li, Y.Wang, K.Forbes, K.M.Vignali, B.S.Heale, P.Saftig, D.Hartmann, R.A.Black, J.J.Rossi, C.P.Blobel et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 2007; 26:494-504; PMID:17245433; http://dx.doi.org/10.1038/sj.emboj.7601520
51. P.Cappello, F.Triebel, M.Iezzi, C.Caorsi, E.Quaglino, P.-L.Lollini, A.Amici, E.D.Carlo, P.Musiani, M.Giovarelli et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c Mice. Cancer Res 2003; 63:2518-25; PMID:12750275
52. Y.Kano, T.Iguchi, H.Matsui, K.Adachi, Y.Sakoda, T.Miyakawa, S.Doi, S.Hazama, H.Nagano, Y.Ueyama et al. Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion. Cancer Sci 2016; 107:398-406; PMID:27079438; http://dx.doi.org/10.1111/cas.12861
53. S.Andreae, S.Buisson, F.Triebel. MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 2003; 102:2130-7; PMID:12775570; http://dx.doi.org/10.1182/blood-2003-01-0273
54. B.Liang, C.Workman, J.Lee, C.Chew, B.M.Dale, L.Colonna, M.Flores, N.Li, E.Schweighoffer, S.Greenberg et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008; 180:5916-26; PMID:18424711; http://dx.doi.org/10.4049/jimmunol.180.9.5916
55. C.J.Workman, D.S.Rice, K.J.Dugger, C.Kurschner, D.A.A.Vignali. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol 2002; 32:2255-63; PMID:12209638; http://dx.doi.org/10.1002/1521-4141(200208)32:8%3c2255::AID-IMMU2255%3e3.0.CO;2-A
56. Y.Hailemichael, Z.Dai, N.Jaffarzad, Y.Ye, M.A.Medina, X.-F.Huang, S.M.Dorta-Estremera, N.R.Greeley, G.Nitti, W.Peng et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med [Internet] 2013 [cited 2013Mar11]; advance online publication. Available from:http://www.nature.com/nm/journal/vaop/ncurrent/abs/nm.3105.html
57. A.Bar-Or, T.Vollmer, J.Antel, D.L.Arnold, C.A.Bodner, D.Campagnolo, J.Gianettoni, F.Jalili, N.Kachuck, Y.Lapierre et al. INduction of antigen-specific tolerance in multiple sclerosis after immunization with dna encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007; 64:1407-15; PMID:17698695; http://dx.doi.org/10.1001/archneur.64.10.nct70002
58. H.E.Klock, E.J.Koesema, M.W.Knuth, S.A.Lesley. Combining the polymerase incomplete primer extension method for cloning and mutagenesis with microscreening to accelerate structural genomics efforts. Proteins Struct Funct Bioinforma 2008; 71:982-994; PMID:18004753; http://dx.doi.org/10.1002/prot.21786
59. B.M.Olson, T.P.Frye, L.E.Johnson, L.Fong, K.L.Knutson, M.L.Disis, D.G.McNeel. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother CII 2010; 59:943-53; PMID:20140431; http://dx.doi.org/10.1007/s00262-010-0820-6